Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: $180.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration February 03, 2021

            Details:

            Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use. GSK will support manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine CVnCoV in 2021.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 14, 2020

            Details:

            CureVac has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a dose of 12 µg.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT162b2

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162b2

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Fosun Pharmaceutical

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 25, 2020

            Details:

            In the ongoing Phase 3 clinical study of the vaccine, BNT162b2 met all primary efficacy endpoints, with an efficacy rate of 95% in preventing symptomatic COVID-19 infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 12, 2020

            Details:

            The exact timing for final approval will depend on how many other shots are given the green light over the next few months. CVnCoV is a mRNA-based vaccines would be used for the treatment of COVID 19 infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVnCoV

            Therapeutic Area: Infections and Infectious Diseases Product Name: CVnCoV

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            The interim data showed that CVnCoV was generally well tolerated across all tested doses (2-12µg) and induced strong binding and neutralizing antibody responses in addition to first indication of T cell activation.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BNT162

            Therapeutic Area: Infections and Infectious Diseases Product Name: BNT162

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: New Zealand government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 12, 2020

            Details:

            The New Zealand government signed a deal on Monday to buy 1.5 million COVID-19 vaccines from Pfizer Inc and Germany’s BioNTech, with delivery potentially as early as the first quarter of 2021.